 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...7374757677787980818283...100101» |
- || samotolisib (LY3023414) / Eli Lilly
Enrollment closed, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Jun 7, 2019
P1, N=156, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting
- | letrozole / generics
Review, Journal: Letrozole pre-treatment prior to medical termination of pregnancy: a systematic review. (Pubmed Central) - Jun 5, 2019
Recruiting --> Active, not recruiting This systematic review demonstrated that a combination of letrozole and misoprostol increased the rate of complete abortion compared to misoprostol alone in some studies, but not in others; additional well designed RCT's are needed.
- | letrozole / generics
Clinical, Journal: Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. (Pubmed Central) - Jun 5, 2019
This systematic review demonstrated that a combination of letrozole and misoprostol increased the rate of complete abortion compared to misoprostol alone in some studies, but not in others; additional well designed RCT's are needed. The Recurrence Score test is validated to predict clinical response to neoadjuvant letrozole in postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer.
- | letrozole / Generic mfg.
Trial completion, Trial completion date: SOLE: Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer (clinicaltrials.gov) - Jun 4, 2019
P3, N=4884, Completed, Sponsor: International Breast Cancer Study Group
The Recurrence Score test is validated to predict clinical response to neoadjuvant letrozole in postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer. Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> May 2019
- || Piqray (alpelisib) / Novartis
Trial completion date, Trial primary completion date, Metastases: BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 4, 2019
P1, N=52, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> May 2019 Trial completion date: May 2019 --> May 2020 | Trial primary completion date: May 2019 --> May 2020
- | letrozole / generics
Review, Journal: Neuroestradiol in regulation of GnRH release. (Pubmed Central) - Jun 4, 2019
Results indicate that letrozole treatment greatly attenuated the EB-induced GnRH and LH surges. Collectively, neuroestradiol released from the hypothalamus appears to be necessary for the positive feedback effect of Eon the GnRH/LH surge.
- |||| letrozole / generics
Lucia Del Mastro MD After 2 years of TAM, extended adj treatment with additional 5y of letrozole, is associated with 19% reduction in iDFS #asco19 #OncoAlert #bcsm (Twitter) - Jun 3, 2019
- |||| letrozole / generics
Clinical: Del Mastro trial of short vs extended adjuvant letrozole, n = 2056, allowed HER2 positive (6% of pts). 10 y DFS showed 3% difference, p .051, 1.2% difference in distant recurrence. No difference in OS at 9 years. 3% difference in osteoporosis. (Twitter) - Jun 3, 2019
- |||| letrozole / generics
Adverse events: Letrozole to 8 years reduces recurrence by about 4-5% compared to 5 years of treatment. HR 0.81. Extended therapy works but trade off is ongoing side effects. (Twitter) - Jun 3, 2019
- || Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap
So, Zoladex and Letrozole? (Twitter) - Jun 3, 2019
- ||| Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap
Daughter with lobular breast cancer had mastectomy, nothing on lymph nodes,she had to stop chemo after 3rd because she was severely https://t.co/6czNQwbgk7 worried if it will have consequences.taking zoladex and letrozole now with https://t.co/MHbQJda3Ji is killing me! (Twitter) - Jun 2, 2019
- |||| Kisqali (ribociclib) / Novartis
Ribociclib and letrozole in #endometrial and #OvarianCancer is tolerable with modest activity - the only responders in ovary were low grade serous - we have several trials planned to explore this combination #gyncsm #ASCO19 (Twitter) - Jun 2, 2019
- | Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Enrollment open, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - May 31, 2019
P1/2, N=25, Recruiting, Sponsor: Academic Thoracic Oncology Medical Investigators Consortium
Collectively, neuroestradiol released from the hypothalamus appears to be necessary for the positive feedback effect of Eon the GnRH/LH surge. Active, not recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer
Clinical, Journal, Combination therapy: Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. (Pubmed Central) - May 30, 2019
P3
These results from PALOMA-2 suggest that palbociclib-letrozole merits consideration as a first-line treatment option for postmenopausal Japanese patients with ER+/HER2‒ ABC. ClinicalTrials.gov: NCT01740427.
- | letrozole / generics, lithium / generics
Preclinical, Journal: Exposure of Hyperandrogen During Pregnancy Causes Depression- and Anxiety-Like Behaviors, and Reduced Hippocampal Neurogenesis in Rat Offspring. (Pubmed Central) - May 30, 2019
The lithium chloride (LICl) was used as an intervention agent since a previous study has shown that lithium chloride could promote neurogenesis in the hippocampus...Furthermore, the Wnt/β-catenin signaling pathway related to normal development of hippocampus was examined but there was no significant changes in Wnt signaling pathway members. Our study provides evidence that exposure of androgen during pregnancy leads to alterations in depressive, anxious and stereotypical behaviors and these phenotypes are possibly associated with changes in neurogenesis in the dentate gyrus.
- | everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - May 30, 2019
P2, N=48, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Our study provides evidence that exposure of androgen during pregnancy leads to alterations in depressive, anxious and stereotypical behaviors and these phenotypes are possibly associated with changes in neurogenesis in the dentate gyrus. Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, HEOR: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - May 30, 2019
P2, N=257, Active, not recruiting, Sponsor: Palleos Healthcare GmbH
Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020 Recruiting --> Active, not recruiting
- | Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, pictilisib (GDC-0941) / Roche
P1 data, Journal, Combination therapy: A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. (Pubmed Central) - May 29, 2019
P1
Combining pictilisib with paclitaxel, with and without bevacizumab or trastuzumab, or letrozole, had a manageable safety profile in patients with locally recurrent or metastatic breast cancer. The combination had antitumor activity, and the additive effect of pictilisib supported further investigation in a randomized study.
- | Kisqali (ribociclib) / Novartis
Journal: Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China. (Pubmed Central) - May 29, 2019
A value-based price for the cost of RIB is $732 or $1170 per 4 weeks for China and Beijing City, respectively. Our study is helpful to inform the multilateral drug price negotiations in China that may be upcoming for RIB.
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Trial completion date, Metastases: To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer (clinicaltrials.gov) - May 29, 2019
P1, N=79, Completed, Sponsor: AstraZeneca
Our study is helpful to inform the multilateral drug price negotiations in China that may be upcoming for RIB. Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019
- | Firmagon (degarelix) / Astellas, Ferring
Trial completion: TRial on the Endocrine Activity of Neoadjuvant Degarelix (clinicaltrials.gov) - May 29, 2019
P2, N=51, Completed, Sponsor: International Breast Cancer Study Group
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019 Active, not recruiting --> Completed
- |||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P3 trial, Combination therapy, Metastases: DAWNA-2: A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - May 28, 2019
P3, N=426, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Enrollment closed, Trial completion date, Trial primary completion date, Tumor mutational burden, Metastases: BioItaLEE: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (clinicaltrials.gov) - May 28, 2019
P3, N=287, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Nov 2022 | Trial primary completion date: Oct 2021 --> Dec 2020
- || letrozole / generics
Recommend period of medical therapy w/ hCG, Clomiphene, letrozole before surgical sperm retrieval for ICSI in men with NOA, particularly w/ Klinefelter? @DrLipshultzTips @DrMEisenberg @DlambJ @jimhotalingmd @malefertdoc @ranjithramamd @satlujan @matt_coward @PNSchlegel @Craigni (Twitter) - May 27, 2019
- | Kisqali (ribociclib) / Novartis
Journal: Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer. (Pubmed Central) - May 24, 2019
There are no available published data regarding the combination of ribociclib and palliative RT. We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC.
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov) - May 24, 2019
P=N/A, N=90, Recruiting, Sponsor: University of Maryland
We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC. Trial completion date: Mar 2019 --> Mar 2022 | Trial primary completion date: Mar 2018 --> Mar 2021
- | letrozole / generics
Journal: The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer. (Pubmed Central) - May 23, 2019
Trial completion date: Mar 2019 --> Mar 2022 | Trial primary completion date: Mar 2018 --> Mar 2021 The discordance of receptors and the dependence of BC on therapies as well as metastatic sites stresses the necessity of early sample taking to offer patients suitable therapy options.
- | letrozole / Generic mfg.
New P1 trial: A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer (clinicaltrials.gov) - May 23, 2019
P1, N=30, Not yet recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
- ||| ipatasertib (RG7440) / Roche
New P1 trial, Metastases: AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) (clinicaltrials.gov) - May 21, 2019
P1, N=60, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion date: Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole (clinicaltrials.gov) - May 21, 2019
P=N/A, N=44, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
The discordance of receptors and the dependence of BC on therapies as well as metastatic sites stresses the necessity of early sample taking to offer patients suitable therapy options. Trial completion date: Dec 2018 --> Dec 2019
- | Kisqali (ribociclib) / Novartis
New trial, Metastases: RibOB: A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer (clinicaltrials.gov) - May 20, 2019
P, N=150, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - May 20, 2019
P4, N=252, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Dec 2018 --> Dec 2019 Trial completion date: Sep 2019 --> Jul 2019 | Trial primary completion date: Sep 2019 --> Jul 2019
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Metastases: PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov) - May 17, 2019
P1, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Sep 2019 --> Jul 2019 | Trial primary completion date: Sep 2019 --> Jul 2019 Trial completion date: Jul 2020 --> Jul 2019
- | Herceptin (trastuzumab) / Roche
Review, Journal: Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. (Pubmed Central) - May 15, 2019
Avitinib, olmutinib, and pelitinib are additional type VI inhibitors in clinical trials for non-small cell lung cancer that target EGFR. Secondary resistance to both targeted and cytotoxic drugs is the norm, and devising and implementing strategies for minimizing or overcoming resistance is an important goal in cancer therapeutics.
- | Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - May 15, 2019
P2, N=22, Recruiting, Sponsor: City of Hope Medical Center
Secondary resistance to both targeted and cytotoxic drugs is the norm, and devising and implementing strategies for minimizing or overcoming resistance is an important goal in cancer therapeutics. Trial completion date: Feb 2020 --> Sep 2020 | Trial primary completion date: Feb 2020 --> Sep 2020
- || letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Trial completion date, Metastases: PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov) - May 14, 2019
P1, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Feb 2020 --> Sep 2020 | Trial primary completion date: Feb 2020 --> Sep 2020 Recruiting --> Active, not recruiting | Trial completion date: Jul 2019 --> Jul 2020
- | New P4 trial: Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) (clinicaltrials.gov) - May 13, 2019
P4, N=218, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- | NN1213 / Novo Nordisk
Trial primary completion date: Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients (clinicaltrials.gov) - May 13, 2019
P=N/A, N=500, Enrolling by invitation, Sponsor: Chinese Academy of Medical Sciences
Recruiting --> Active, not recruiting | Trial completion date: Jul 2019 --> Jul 2020 Trial primary completion date: Nov 2017 --> Jan 2020
- | Ibrance (palbociclib) / Pfizer
Clinical, Journal, HEOR, Real-World Evidence: Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. (Pubmed Central) - May 9, 2019
The occurrence of grade 3 and 4 neutropenia (based on laboratory results) was consistent with the rates of grade 3 and 4 neutropenia in two phase-III studies (PALOMA-2, 56% and 10%; PALOMA-3, 55% and 11%, respectively). Understanding palbociclib utilization in real-world patients and how drug dosing and monitoring are performed aids in the understanding of safe and effective use of the drug.
- || letrozole / generics
May 2019: The novel use of combination of Letrozole and Clomid to induce ovulation https://t.co/A1GbSBJOB4. Pleasure to join the conversation! #pcosfertility (Twitter) - May 9, 2019
- |||| Kisqali (ribociclib) / Novartis
New P2 trial, Combination therapy, Metastases: FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (clinicaltrials.gov) - May 8, 2019
P2, N=194, Recruiting, Sponsor: Fondazione Sandro Pitigliani
- | Ibrance (palbociclib) / Pfizer
Clinical, Journal: Pharmacological profile and clinical findings of palbociclib (IBRANCE capsule 25 mg/125 mg) (Pubmed Central) - May 7, 2019
In the PALOMA-3 study, the combination of palbociclib and fulvestrant was associated with significant improvements in PFS compared with fulvestrant plus placebo in patients with metastatic breast cancer. The rate of dose reduction or interruption of dosing by adverse events is higher in palbociclib group compared with placebo group in both studies while the rate of discontinuation of treatment was comparable.
- || Ibrance (palbociclib) / Pfizer
New P2 trial: LACOG1018: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (clinicaltrials.gov) - May 2, 2019
P2, N=39, Not yet recruiting, Sponsor: Latin American Cooperative Oncology Group
- | letrozole / generics
Preclinical, Journal: Orchiectomy and letrozole differentially regulate synaptic plasticity and spatial memory in a manner that is mediated by SRC-1 in the hippocampus of male mice. (Pubmed Central) - May 2, 2019
These results demonstrate that testicular androgens play a limited role, whereas local E2 is more important for cognition, which may explain why castrated men such as eunuchs usually do not have cognitive disorders. These results also suggest a pivotal role of SRC-1 in the action of steroids; thus, SRC-1 may serve as a novel therapeutic target for cognitive disorders.
- | Journal: Comprehensive Genomic Profiling Aids in Treatment of a Metastatic Endometrial Cancer. (Pubmed Central) - May 2, 2019
Additionally, clinical benefit from an mTOR inhibitor may reflect a response to targeting the alteration in PIK3CA or TSC2 . More research is needed to understand the activity of FGFR3-TACC3 fusions on tumors and to discover additional therapeutic options for endometrial carcinoma patients with this gene fusion.
- ||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial primary completion date, Metastases: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - May 2, 2019
P2, N=55, Recruiting, Sponsor: Washington University School of Medicine
More research is needed to understand the activity of FGFR3-TACC3 fusions on tumors and to discover additional therapeutic options for endometrial carcinoma patients with this gene fusion. Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2019 --> Aug 2019
- | letrozole / generics
Clinical, Journal: Aromatase Inhibitors Such as Letrozole (Femara) vs. Clomiphene (Clomid) for Subfertile Women with PCOS. (Pubmed Central) - May 1, 2019
Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2019 --> Aug 2019 No abstract available
- | buparlisib (BKM120) / Novartis, Adlai Nortye
Journal, Combination therapy, Cancer stem cells: NVP-BKM120 in combination with letrozole inhibit human breast cancer stem cells via PI3K/mTOR pathway (Pubmed Central) - Apr 30, 2019
PI3K/Akt/mTOR pathway effects on letrozole resistance by regulating BCBSs characteristics. Combination of PI3K inhibitor BKM120 and letrozole could reduce letrozole resistance.
- | letrozole / generics
Clinical, Journal, Monotherapy: Letrozole Monotherapy in Pre- and Early-Pubertal Boys Does Not Increase Adult Height. (Pubmed Central) - Apr 27, 2019
The Lz-treated boys had similar adult heights with the subjects who received Pl for 2 years, which indicates that the treatment is not beneficial when given to pre- or early-pubertal boys. Previously observed vertebral deformities ameliorated during follow-up, which supports the skeletal safety of Lz therapy in children and adolescents.
- | Faslodex (fulvestrant) / AstraZeneca
Clinical, Journal, HEOR: Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK. (Pubmed Central) - Apr 27, 2019
Previously observed vertebral deformities ameliorated during follow-up, which supports the skeletal safety of Lz therapy in children and adolescents. Results suggest that fulvestrant could potentially be a cost-effective option compared with other endocrine monotherapies (anastrozole, letrozole, and tamoxifen) for treating endocrine therapy-naïve, postmenopausal women with HR+, locally advanced or metastatic breast cancer.